APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenza (Flu) Antiviral Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Influenza (Flu) Antiviral Drugs Market Analysis and Forecast 2026-2032

2 January 2026217 pages

Choose your research edition.

Industry ResearchInfluenza (Flu) Antiviral Drugs Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza (Flu) Antiviral Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Influenza (Flu) Antiviral Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza (Flu) Antiviral Drugs Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza (Flu) Antiviral Drugs Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Influenza (Flu) Antiviral Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Influenza (Flu) Antiviral Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Influenza (Flu) Antiviral Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Influenza (Flu) Antiviral Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Influenza (Flu) Antiviral Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Influenza (Flu) Antiviral Drugs include Allergan, Aurobindo Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Bristol-Myers-Squibb, Cipla, F. Hoffmann-La Roche, Gilead Sciences and GlaxoSmithKline (GSK), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Influenza (Flu) Antiviral Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Influenza (Flu) Antiviral Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Influenza (Flu) Antiviral Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Influenza (Flu) Antiviral Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Influenza (Flu) Antiviral Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Influenza (Flu) Antiviral Drugs sales, projected growth trends, production technology, application and end-user industry.

Influenza (Flu) Antiviral Drugs Segment by Company

Allergan

Aurobindo Pharma

Boehringer Ingelheim

Bristol-Myers Squibb

Bristol-Myers-Squibb

Cipla

F. Hoffmann-La Roche

Gilead Sciences

GlaxoSmithKline (GSK)

Merck & Co. (MSD)

Novo Nordisk

Teva Pharmaceutical Industries

AstraZeneca

AbbVie

Amgen

Bayer

Pfizer

Eli Lilly

Roche

Mylan

Novartis

Johnson & Johnson

Sanofi

Teva

Takeda

Influenza (Flu) Antiviral Drugs Segment by Type

Neuraminidase Inhibitors

Reverse Transcriptase Inhibitors

Broad-spectrum Antiviral Drugs

Protein Inhibitors

Penetration and Dehulling Inhibitors

DNA Polymerase Inhibitors

Influenza (Flu) Antiviral Drugs Segment by Application

Clinic

Hospital

Household

Others

Influenza (Flu) Antiviral Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza (Flu) Antiviral Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza (Flu) Antiviral Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza (Flu) Antiviral Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Influenza (Flu) Antiviral Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Influenza (Flu) Antiviral Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Influenza (Flu) Antiviral Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Neuraminidase Inhibitors Major Manufacturers Table 3. Reverse Transcriptase Inhibitors Major Manufacturers Table 4. Broad-spectrum Antiviral Drugs Major Manufacturers Table 5. Protein Inhibitors Major Manufacturers Table 6. Penetration and Dehulling Inhibitors Major Manufacturers Table 7. DNA Polymerase Inhibitors Major Manufacturers Table 8. Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Clinic Major Manufacturers Table 10. Hospital Major Manufacturers Table 11. Household Major Manufacturers Table 12. Others Major Manufacturers Table 13. Influenza (Flu) Antiviral Drugs Industry Trends Table 14. Influenza (Flu) Antiviral Drugs Industry Drivers Table 15. Influenza (Flu) Antiviral Drugs Industry Opportunities and Challenges Table 16. Influenza (Flu) Antiviral Drugs Industry Restraints Table 17. Global Influenza (Flu) Antiviral Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Influenza (Flu) Antiviral Drugs Revenue by Region (2021-2026) & (US$ Million) Table 19. Global Influenza (Flu) Antiviral Drugs Revenue by Region (2027-2032) & (US$ Million) Table 20. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2021-2026) Table 21. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2027-2032) Table 22. Global Influenza (Flu) Antiviral Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 23. Global Influenza (Flu) Antiviral Drugs Sales by Region (2021-2026) & (K Units) Table 24. Global Influenza (Flu) Antiviral Drugs Sales by Region (2027-2032) & (K Units) Table 25. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Region (2021-2026) Table 26. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Region (2027-2032) Table 27. Global Influenza (Flu) Antiviral Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Manufacturers (2021-2026) Table 29. Global Influenza (Flu) Antiviral Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Manufacturers (2021-2026) Table 31. Global Influenza (Flu) Antiviral Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 32. Global Influenza (Flu) Antiviral Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 33. Global Influenza (Flu) Antiviral Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 34. Global Influenza (Flu) Antiviral Drugs Manufacturers, Product Type & Application Table 35. Global Influenza (Flu) Antiviral Drugs Manufacturers' Establishment Date Table 36. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 37. Global Influenza (Flu) Antiviral Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 38. Global Influenza (Flu) Antiviral Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2026) & (US$ Million) Table 40. Global Influenza (Flu) Antiviral Drugs Revenue by Type (2027-2032) & (US$ Million) Table 41. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2021-2026) Table 42. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2027-2032) Table 43. Global Influenza (Flu) Antiviral Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 44. Global Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units) Table 45. Global Influenza (Flu) Antiviral Drugs Sales by Type (2027-2032) & (K Units) Table 46. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2021-2026) Table 47. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2027-2032) Table 48. Global Influenza (Flu) Antiviral Drugs Price by Type (2021-2026) & (US$/Unit) Table 49. Global Influenza (Flu) Antiviral Drugs Price by Type (2027-2032) & (US$/Unit) Table 50. Global Influenza (Flu) Antiviral Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2026) & (US$ Million) Table 52. Global Influenza (Flu) Antiviral Drugs Revenue by Application (2027-2032) & (US$ Million) Table 53. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2021-2026) Table 54. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2027-2032) Table 55. Global Influenza (Flu) Antiviral Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 56. Global Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units) Table 57. Global Influenza (Flu) Antiviral Drugs Sales by Application (2027-2032) & (K Units) Table 58. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2021-2026) Table 59. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2027-2032) Table 60. Global Influenza (Flu) Antiviral Drugs Price by Application (2021-2026) & (US$/Unit) Table 61. Global Influenza (Flu) Antiviral Drugs Price by Application (2027-2032) & (US$/Unit) Table 62. Allergan Company Information Table 63. Allergan Business Overview Table 64. Allergan Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Allergan Influenza (Flu) Antiviral Drugs Product Portfolio Table 66. Allergan Recent Development Table 67. Aurobindo Pharma Company Information Table 68. Aurobindo Pharma Business Overview Table 69. Aurobindo Pharma Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Aurobindo Pharma Influenza (Flu) Antiviral Drugs Product Portfolio Table 71. Aurobindo Pharma Recent Development Table 72. Boehringer Ingelheim Company Information Table 73. Boehringer Ingelheim Business Overview Table 74. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product Portfolio Table 76. Boehringer Ingelheim Recent Development Table 77. Bristol-Myers Squibb Company Information Table 78. Bristol-Myers Squibb Business Overview Table 79. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product Portfolio Table 81. Bristol-Myers Squibb Recent Development Table 82. Bristol-Myers-Squibb Company Information Table 83. Bristol-Myers-Squibb Business Overview Table 84. Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Product Portfolio Table 86. Bristol-Myers-Squibb Recent Development Table 87. Cipla Company Information Table 88. Cipla Business Overview Table 89. Cipla Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Cipla Influenza (Flu) Antiviral Drugs Product Portfolio Table 91. Cipla Recent Development Table 92. F. Hoffmann-La Roche Company Information Table 93. F. Hoffmann-La Roche Business Overview Table 94. F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Product Portfolio Table 96. F. Hoffmann-La Roche Recent Development Table 97. Gilead Sciences Company Information Table 98. Gilead Sciences Business Overview Table 99. Gilead Sciences Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Gilead Sciences Influenza (Flu) Antiviral Drugs Product Portfolio Table 101. Gilead Sciences Recent Development Table 102. GlaxoSmithKline (GSK) Company Information Table 103. GlaxoSmithKline (GSK) Business Overview Table 104. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product Portfolio Table 106. GlaxoSmithKline (GSK) Recent Development Table 107. Merck & Co. (MSD) Company Information Table 108. Merck & Co. (MSD) Business Overview Table 109. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product Portfolio Table 111. Merck & Co. (MSD) Recent Development Table 112. Novo Nordisk Company Information Table 113. Novo Nordisk Business Overview Table 114. Novo Nordisk Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Novo Nordisk Influenza (Flu) Antiviral Drugs Product Portfolio Table 116. Novo Nordisk Recent Development Table 117. Teva Pharmaceutical Industries Company Information Table 118. Teva Pharmaceutical Industries Business Overview Table 119. Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Product Portfolio Table 121. Teva Pharmaceutical Industries Recent Development Table 122. AstraZeneca Company Information Table 123. AstraZeneca Business Overview Table 124. AstraZeneca Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. AstraZeneca Influenza (Flu) Antiviral Drugs Product Portfolio Table 126. AstraZeneca Recent Development Table 127. AbbVie Company Information Table 128. AbbVie Business Overview Table 129. AbbVie Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. AbbVie Influenza (Flu) Antiviral Drugs Product Portfolio Table 131. AbbVie Recent Development Table 132. Amgen Company Information Table 133. Amgen Business Overview Table 134. Amgen Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Amgen Influenza (Flu) Antiviral Drugs Product Portfolio Table 136. Amgen Recent Development Table 137. Bayer Company Information Table 138. Bayer Business Overview Table 139. Bayer Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Bayer Influenza (Flu) Antiviral Drugs Product Portfolio Table 141. Bayer Recent Development Table 142. Pfizer Company Information Table 143. Pfizer Business Overview Table 144. Pfizer Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Pfizer Influenza (Flu) Antiviral Drugs Product Portfolio Table 146. Pfizer Recent Development Table 147. Eli Lilly Company Information Table 148. Eli Lilly Business Overview Table 149. Eli Lilly Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Eli Lilly Influenza (Flu) Antiviral Drugs Product Portfolio Table 151. Eli Lilly Recent Development Table 152. Roche Company Information Table 153. Roche Business Overview Table 154. Roche Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Roche Influenza (Flu) Antiviral Drugs Product Portfolio Table 156. Roche Recent Development Table 157. Mylan Company Information Table 158. Mylan Business Overview Table 159. Mylan Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Mylan Influenza (Flu) Antiviral Drugs Product Portfolio Table 161. Mylan Recent Development Table 162. Novartis Company Information Table 163. Novartis Business Overview Table 164. Novartis Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Novartis Influenza (Flu) Antiviral Drugs Product Portfolio Table 166. Novartis Recent Development Table 167. Johnson & Johnson Company Information Table 168. Johnson & Johnson Business Overview Table 169. Johnson & Johnson Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. Johnson & Johnson Influenza (Flu) Antiviral Drugs Product Portfolio Table 171. Johnson & Johnson Recent Development Table 172. Sanofi Company Information Table 173. Sanofi Business Overview Table 174. Sanofi Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 175. Sanofi Influenza (Flu) Antiviral Drugs Product Portfolio Table 176. Sanofi Recent Development Table 177. Teva Company Information Table 178. Teva Business Overview Table 179. Teva Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 180. Teva Influenza (Flu) Antiviral Drugs Product Portfolio Table 181. Teva Recent Development Table 182. Takeda Company Information Table 183. Takeda Business Overview Table 184. Takeda Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 185. Takeda Influenza (Flu) Antiviral Drugs Product Portfolio Table 186. Takeda Recent Development Table 187. North America Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2026) & (US$ Million) Table 188. North America Influenza (Flu) Antiviral Drugs Revenue by Type (2027-2032) & (US$ Million) Table 189. North America Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units) Table 190. North America Influenza (Flu) Antiviral Drugs Sales by Type (2027-2032) & (K Units) Table 191. North America Influenza (Flu) Antiviral Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 192. North America Influenza (Flu) Antiviral Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 193. North America Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2026) & (US$ Million) Table 194. North America Influenza (Flu) Antiviral Drugs Revenue by Application (2027-2032) & (US$ Million) Table 195. North America Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units) Table 196. North America Influenza (Flu) Antiviral Drugs Sales by Application (2027-2032) & (K Units) Table 197. North America Influenza (Flu) Antiviral Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 198. North America Influenza (Flu) Antiviral Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 199. North America Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 200. North America Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 201. North America Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 202. North America Influenza (Flu) Antiviral Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 203. North America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 204. North America Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units) Table 205. North America Influenza (Flu) Antiviral Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 206. North America Influenza (Flu) Antiviral Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 207. United States Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 208. Canada Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 209. Europe Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2026) & (US$ Million) Table 210. Europe Influenza (Flu) Antiviral Drugs Revenue by Type (2027-2032) & (US$ Million) Table 211. Europe Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units) Table 212. Europe Influenza (Flu) Antiviral Drugs Sales by Type (2027-2032) & (K Units) Table 213. Europe Influenza (Flu) Antiviral Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 214. Europe Influenza (Flu) Antiviral Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 215. Europe Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2026) & (US$ Million) Table 216. Europe Influenza (Flu) Antiviral Drugs Revenue by Application (2027-2032) & (US$ Million) Table 217. Europe Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units) Table 218. Europe Influenza (Flu) Antiviral Drugs Sales by Application (2027-2032) & (K Units) Table 219. Europe Influenza (Flu) Antiviral Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 220. Europe Influenza (Flu) Antiviral Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 221. Europe Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 222. Europe Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 223. Europe Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 224. Europe Influenza (Flu) Antiviral Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 225. Europe Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 226. Europe Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units) Table 227. Europe Influenza (Flu) Antiviral Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 228. Europe Influenza (Flu) Antiviral Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 229. Germany Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 230. France Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 231. U.K. Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 232. Italy Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 233. Netherlands Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 234. Nordic Countries Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 235. China Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2026) & (US$ Million) Table 236. China Influenza (Flu) Antiviral Drugs Revenue by Type (2027-2032) & (US$ Million) Table 237. China Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units) Table 238. China Influenza (Flu) Antiviral Drugs Sales by Type (2027-2032) & (K Units) Table 239. China Influenza (Flu) Antiviral Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 240. China Influenza (Flu) Antiviral Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 241. China Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2026) & (US$ Million) Table 242. China Influenza (Flu) Antiviral Drugs Revenue by Application (2027-2032) & (US$ Million) Table 243. China Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units) Table 244. China Influenza (Flu) Antiviral Drugs Sales by Application (2027-2032) & (K Units) Table 245. China Influenza (Flu) Antiviral Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 246. China Influenza (Flu) Antiviral Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 247. Asia Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2026) & (US$ Million) Table 248. Asia Influenza (Flu) Antiviral Drugs Revenue by Type (2027-2032) & (US$ Million) Table 249. Asia Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units) Table 250. Asia Influenza (Flu) Antiviral Drugs Sales by Type (2027-2032) & (K Units) Table 251. Asia Influenza (Flu) Antiviral Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 252. Asia Influenza (Flu) Antiviral Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 253. Asia Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2026) & (US$ Million) Table 254. Asia Influenza (Flu) Antiviral Drugs Revenue by Application (2027-2032) & (US$ Million) Table 255. Asia Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units) Table 256. Asia Influenza (Flu) Antiviral Drugs Sales by Application (2027-2032) & (K Units) Table 257. Asia Influenza (Flu) Antiviral Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 258. Asia Influenza (Flu) Antiviral Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 259. Asia Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 260. Asia Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 261. Asia Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 262. Asia Influenza (Flu) Antiviral Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 263. Asia Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 264. Asia Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units) Table 265. Asia Influenza (Flu) Antiviral Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 266. Asia Influenza (Flu) Antiviral Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 267. Japan Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 268. South Korea Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 269. India Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 270. Australia Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 271. China Taiwan Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 272. Southeast Asia Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 273. SAMEA Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2026) & (US$ Million) Table 274. SAMEA Influenza (Flu) Antiviral Drugs Revenue by Type (2027-2032) & (US$ Million) Table 275. SAMEA Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units) Table 276. SAMEA Influenza (Flu) Antiviral Drugs Sales by Type (2027-2032) & (K Units) Table 277. SAMEA Influenza (Flu) Antiviral Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 278. SAMEA Influenza (Flu) Antiviral Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 279. SAMEA Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2026) & (US$ Million) Table 280. SAMEA Influenza (Flu) Antiviral Drugs Revenue by Application (2027-2032) & (US$ Million) Table 281. SAMEA Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units) Table 282. SAMEA Influenza (Flu) Antiviral Drugs Sales by Application (2027-2032) & (K Units) Table 283. SAMEA Influenza (Flu) Antiviral Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 284. SAMEA Influenza (Flu) Antiviral Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 285. SAMEA Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 286. SAMEA Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 287. SAMEA Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 288. SAMEA Influenza (Flu) Antiviral Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 289. SAMEA Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 290. SAMEA Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units) Table 291. SAMEA Influenza (Flu) Antiviral Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 292. SAMEA Influenza (Flu) Antiviral Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 293. Brazil Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 294. Argentina Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 295. Chile Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 296. Colombia Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 297. Peru Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 298. Saudi Arabia Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 299. Israel Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 300. UAE Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 301. Turkey Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 302. Iran Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 303. Egypt Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Table 304. Key Raw Materials Table 305. Raw Materials Key Suppliers Table 306. Influenza (Flu) Antiviral Drugs Distributors List Table 307. Influenza (Flu) Antiviral Drugs Customers List Table 308. Research Programs/Design for This Report Table 309. Authors List of This Report Table 310. Secondary Sources Table 311. Primary Sources List of Figures Figure 1. Influenza (Flu) Antiviral Drugs Image Figure 2. Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza (Flu) Antiviral Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Neuraminidase Inhibitors Image Figure 5. Reverse Transcriptase Inhibitors Image Figure 6. Broad-spectrum Antiviral Drugs Image Figure 7. Protein Inhibitors Image Figure 8. Penetration and Dehulling Inhibitors Image Figure 9. DNA Polymerase Inhibitors Image Figure 10. Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Influenza (Flu) Antiviral Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 12. Clinic Image Figure 13. Hospital Image Figure 14. Household Image Figure 15. Others Image Figure 16. Global Influenza (Flu) Antiviral Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Figure 18. Global Influenza (Flu) Antiviral Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2021-2032) Figure 21. Global Influenza (Flu) Antiviral Drugs Sales (2021-2032) & (K Units) Figure 22. Global Influenza (Flu) Antiviral Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 23. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Region (2021-2032) Figure 24. US & Canada & Mexico Influenza (Flu) Antiviral Drugs Sales YoY (2021-2032) & (K Units) Figure 25. Europe Influenza (Flu) Antiviral Drugs Sales YoY (2021-2032) & (K Units) Figure 26. China Influenza (Flu) Antiviral Drugs Sales YoY (2021-2032) & (K Units) Figure 27. Asia (Excluding China) Influenza (Flu) Antiviral Drugs Sales YoY (2021-2032) & (K Units) Figure 28. South America, Middle East and Africa Influenza (Flu) Antiviral Drugs Sales YoY (2021-2032) & (K Units) Figure 29. Global Influenza (Flu) Antiviral Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global Influenza (Flu) Antiviral Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global Influenza (Flu) Antiviral Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2021-2032) Figure 35. Global Influenza (Flu) Antiviral Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 36. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 37. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2021-2032) Figure 38. Global Influenza (Flu) Antiviral Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 39. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2021-2032) Figure 41. Global Influenza (Flu) Antiviral Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 42. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 43. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2021-2032) Figure 44. North America Influenza (Flu) Antiviral Drugs Revenue Share by Type (2021-2032) Figure 45. North America Influenza (Flu) Antiviral Drugs Sales Share by Type (2021-2032) Figure 46. North America Influenza (Flu) Antiviral Drugs Revenue Share by Application (2021-2032) Figure 47. North America Influenza (Flu) Antiviral Drugs Sales Share by Application (2021-2032) Figure 48. North America Influenza (Flu) Antiviral Drugs Revenue Share by Country (2021-2032) Figure 49. North America Influenza (Flu) Antiviral Drugs Sales Share by Country (2021-2032) Figure 50. Europe Influenza (Flu) Antiviral Drugs Revenue Share by Type (2021-2032) Figure 51. Europe Influenza (Flu) Antiviral Drugs Sales Share by Type (2021-2032) Figure 52. Europe Influenza (Flu) Antiviral Drugs Revenue Share by Application (2021-2032) Figure 53. Europe Influenza (Flu) Antiviral Drugs Sales Share by Application (2021-2032) Figure 54. Europe Influenza (Flu) Antiviral Drugs Revenue Share by Country (2021-2032) Figure 55. Europe Influenza (Flu) Antiviral Drugs Sales Share by Country (2021-2032) Figure 56. China Influenza (Flu) Antiviral Drugs Revenue Share by Type (2021-2032) Figure 57. China Influenza (Flu) Antiviral Drugs Sales Share by Type (2021-2032) Figure 58. China Influenza (Flu) Antiviral Drugs Revenue Share by Application (2021-2032) Figure 59. China Influenza (Flu) Antiviral Drugs Sales Share by Application (2021-2032) Figure 60. Asia Influenza (Flu) Antiviral Drugs Revenue Share by Type (2021-2032) Figure 61. Asia Influenza (Flu) Antiviral Drugs Sales Share by Type (2021-2032) Figure 62. Asia Influenza (Flu) Antiviral Drugs Revenue Share by Application (2021-2032) Figure 63. Asia Influenza (Flu) Antiviral Drugs Sales Share by Application (2021-2032) Figure 64. Asia Influenza (Flu) Antiviral Drugs Revenue Share by Country (2021-2032)

Scope & coverage.

Types
  • Neuraminidase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Broad-spectrum Antiviral Drugs
  • Protein Inhibitors
  • Penetration and Dehulling Inhibitors
  • DNA Polymerase Inhibitors
Applications
  • Clinic
  • Hospital
  • Household
  • Others
Companies covered
  • Allergan
  • Aurobindo Pharma
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Bristol-Myers-Squibb
  • Cipla
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Merck & Co. (MSD)
  • Novo Nordisk
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • AbbVie
  • Amgen
  • Bayer
  • Pfizer
  • Eli Lilly
  • Roche
  • Mylan
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Teva
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Influenza (Flu) Antiviral Drugs Market by Type
  3. 1.2.1 Global Influenza (Flu) Antiviral Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Neuraminidase Inhibitors
  5. 1.2.3 Reverse Transcriptase Inhibitors
  6. 1.2.4 Broad-spectrum Antiviral Drugs
  7. 1.2.5 Protein Inhibitors
  8. 1.2.6 Penetration and Dehulling Inhibitors
  9. 1.2.7 DNA Polymerase Inhibitors
  10. 1.3 Influenza (Flu) Antiviral Drugs Market by Application
  11. 1.3.1 Global Influenza (Flu) Antiviral Drugs Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Clinic
  13. 1.3.3 Hospital
  14. 1.3.4 Household
  15. 1.3.5 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Influenza (Flu) Antiviral Drugs Market Dynamics
  1. 2.1 Influenza (Flu) Antiviral Drugs Industry Trends
  2. 2.2 Influenza (Flu) Antiviral Drugs Industry Drivers
  3. 2.3 Influenza (Flu) Antiviral Drugs Industry Opportunities and Challenges
  4. 2.4 Influenza (Flu) Antiviral Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Influenza (Flu) Antiviral Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Influenza (Flu) Antiviral Drugs Revenue by Region
  3. 3.2.1 Global Influenza (Flu) Antiviral Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Influenza (Flu) Antiviral Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Influenza (Flu) Antiviral Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Influenza (Flu) Antiviral Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Influenza (Flu) Antiviral Drugs Sales by Region
  9. 3.4.1 Global Influenza (Flu) Antiviral Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Influenza (Flu) Antiviral Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Influenza (Flu) Antiviral Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Influenza (Flu) Antiviral Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Influenza (Flu) Antiviral Drugs Revenue by Manufacturers
  2. 4.1.1 Global Influenza (Flu) Antiviral Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Influenza (Flu) Antiviral Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Influenza (Flu) Antiviral Drugs Sales by Manufacturers
  6. 4.2.1 Global Influenza (Flu) Antiviral Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Influenza (Flu) Antiviral Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Influenza (Flu) Antiviral Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Influenza (Flu) Antiviral Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Influenza (Flu) Antiviral Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Influenza (Flu) Antiviral Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Influenza (Flu) Antiviral Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Influenza (Flu) Antiviral Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Influenza (Flu) Antiviral Drugs Market CR5 and HHI
  16. 4.8.2 2025 Influenza (Flu) Antiviral Drugs Tier 1, Tier 2, and Tier 3
5 Influenza (Flu) Antiviral Drugs Market by Type
  1. 5.1 Global Influenza (Flu) Antiviral Drugs Revenue by Type
  2. 5.1.1 Global Influenza (Flu) Antiviral Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Influenza (Flu) Antiviral Drugs Sales by Type
  6. 5.2.1 Global Influenza (Flu) Antiviral Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Influenza (Flu) Antiviral Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Influenza (Flu) Antiviral Drugs Price by Type
6 Influenza (Flu) Antiviral Drugs Market by Application
  1. 6.1 Global Influenza (Flu) Antiviral Drugs Revenue by Application
  2. 6.1.1 Global Influenza (Flu) Antiviral Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Influenza (Flu) Antiviral Drugs Sales by Application
  6. 6.2.1 Global Influenza (Flu) Antiviral Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Influenza (Flu) Antiviral Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Influenza (Flu) Antiviral Drugs Price by Application
7 Company Profiles
  1. 7.1 Allergan
  2. 7.1.1 Allergan Company Information
  3. 7.1.2 Allergan Business Overview
  4. 7.1.3 Allergan Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Allergan Influenza (Flu) Antiviral Drugs Product Portfolio
  6. 7.1.5 Allergan Recent Developments
  7. 7.2 Aurobindo Pharma
  8. 7.2.1 Aurobindo Pharma Company Information
  9. 7.2.2 Aurobindo Pharma Business Overview
  10. 7.2.3 Aurobindo Pharma Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Aurobindo Pharma Influenza (Flu) Antiviral Drugs Product Portfolio
  12. 7.2.5 Aurobindo Pharma Recent Developments
  13. 7.3 Boehringer Ingelheim
  14. 7.3.1 Boehringer Ingelheim Company Information
  15. 7.3.2 Boehringer Ingelheim Business Overview
  16. 7.3.3 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product Portfolio
  18. 7.3.5 Boehringer Ingelheim Recent Developments
  19. 7.4 Bristol-Myers Squibb
  20. 7.4.1 Bristol-Myers Squibb Company Information
  21. 7.4.2 Bristol-Myers Squibb Business Overview
  22. 7.4.3 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Recent Developments
  25. 7.5 Bristol-Myers-Squibb
  26. 7.5.1 Bristol-Myers-Squibb Company Information
  27. 7.5.2 Bristol-Myers-Squibb Business Overview
  28. 7.5.3 Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
  30. 7.5.5 Bristol-Myers-Squibb Recent Developments
  31. 7.6 Cipla
  32. 7.6.1 Cipla Company Information
  33. 7.6.2 Cipla Business Overview
  34. 7.6.3 Cipla Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Cipla Influenza (Flu) Antiviral Drugs Product Portfolio
  36. 7.6.5 Cipla Recent Developments
  37. 7.7 F. Hoffmann-La Roche
  38. 7.7.1 F. Hoffmann-La Roche Company Information
  39. 7.7.2 F. Hoffmann-La Roche Business Overview
  40. 7.7.3 F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Product Portfolio
  42. 7.7.5 F. Hoffmann-La Roche Recent Developments
  43. 7.8 Gilead Sciences
  44. 7.8.1 Gilead Sciences Company Information
  45. 7.8.2 Gilead Sciences Business Overview
  46. 7.8.3 Gilead Sciences Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Gilead Sciences Influenza (Flu) Antiviral Drugs Product Portfolio
  48. 7.8.5 Gilead Sciences Recent Developments
  49. 7.9 GlaxoSmithKline (GSK)
  50. 7.9.1 GlaxoSmithKline (GSK) Company Information
  51. 7.9.2 GlaxoSmithKline (GSK) Business Overview
  52. 7.9.3 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product Portfolio
  54. 7.9.5 GlaxoSmithKline (GSK) Recent Developments
  55. 7.10 Merck & Co. (MSD)
  56. 7.10.1 Merck & Co. (MSD) Company Information
  57. 7.10.2 Merck & Co. (MSD) Business Overview
  58. 7.10.3 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product Portfolio
  60. 7.10.5 Merck & Co. (MSD) Recent Developments
  61. 7.11 Novo Nordisk
  62. 7.11.1 Novo Nordisk Company Information
  63. 7.11.2 Novo Nordisk Business Overview
  64. 7.11.3 Novo Nordisk Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Novo Nordisk Influenza (Flu) Antiviral Drugs Product Portfolio
  66. 7.11.5 Novo Nordisk Recent Developments
  67. 7.12 Teva Pharmaceutical Industries
  68. 7.12.1 Teva Pharmaceutical Industries Company Information
  69. 7.12.2 Teva Pharmaceutical Industries Business Overview
  70. 7.12.3 Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Product Portfolio
  72. 7.12.5 Teva Pharmaceutical Industries Recent Developments
  73. 7.13 AstraZeneca
  74. 7.13.1 AstraZeneca Company Information
  75. 7.13.2 AstraZeneca Business Overview
  76. 7.13.3 AstraZeneca Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 AstraZeneca Influenza (Flu) Antiviral Drugs Product Portfolio
  78. 7.13.5 AstraZeneca Recent Developments
  79. 7.14 AbbVie
  80. 7.14.1 AbbVie Company Information
  81. 7.14.2 AbbVie Business Overview
  82. 7.14.3 AbbVie Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 AbbVie Influenza (Flu) Antiviral Drugs Product Portfolio
  84. 7.14.5 AbbVie Recent Developments
  85. 7.15 Amgen
  86. 7.15.1 Amgen Company Information
  87. 7.15.2 Amgen Business Overview
  88. 7.15.3 Amgen Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Amgen Influenza (Flu) Antiviral Drugs Product Portfolio
  90. 7.15.5 Amgen Recent Developments
  91. 7.16 Bayer
  92. 7.16.1 Bayer Company Information
  93. 7.16.2 Bayer Business Overview
  94. 7.16.3 Bayer Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Bayer Influenza (Flu) Antiviral Drugs Product Portfolio
  96. 7.16.5 Bayer Recent Developments
  97. 7.17 Pfizer
  98. 7.17.1 Pfizer Company Information
  99. 7.17.2 Pfizer Business Overview
  100. 7.17.3 Pfizer Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Pfizer Influenza (Flu) Antiviral Drugs Product Portfolio
  102. 7.17.5 Pfizer Recent Developments
  103. 7.18 Eli Lilly
  104. 7.18.1 Eli Lilly Company Information
  105. 7.18.2 Eli Lilly Business Overview
  106. 7.18.3 Eli Lilly Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Eli Lilly Influenza (Flu) Antiviral Drugs Product Portfolio
  108. 7.18.5 Eli Lilly Recent Developments
  109. 7.19 Roche
  110. 7.19.1 Roche Company Information
  111. 7.19.2 Roche Business Overview
  112. 7.19.3 Roche Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Roche Influenza (Flu) Antiviral Drugs Product Portfolio
  114. 7.19.5 Roche Recent Developments
  115. 7.20 Mylan
  116. 7.20.1 Mylan Company Information
  117. 7.20.2 Mylan Business Overview
  118. 7.20.3 Mylan Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Mylan Influenza (Flu) Antiviral Drugs Product Portfolio
  120. 7.20.5 Mylan Recent Developments
  121. 7.21 Novartis
  122. 7.21.1 Novartis Company Information
  123. 7.21.2 Novartis Business Overview
  124. 7.21.3 Novartis Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Novartis Influenza (Flu) Antiviral Drugs Product Portfolio
  126. 7.21.5 Novartis Recent Developments
  127. 7.22 Johnson & Johnson
  128. 7.22.1 Johnson & Johnson Company Information
  129. 7.22.2 Johnson & Johnson Business Overview
  130. 7.22.3 Johnson & Johnson Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Johnson & Johnson Influenza (Flu) Antiviral Drugs Product Portfolio
  132. 7.22.5 Johnson & Johnson Recent Developments
  133. 7.23 Sanofi
  134. 7.23.1 Sanofi Company Information
  135. 7.23.2 Sanofi Business Overview
  136. 7.23.3 Sanofi Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 Sanofi Influenza (Flu) Antiviral Drugs Product Portfolio
  138. 7.23.5 Sanofi Recent Developments
  139. 7.24 Teva
  140. 7.24.1 Teva Company Information
  141. 7.24.2 Teva Business Overview
  142. 7.24.3 Teva Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 Teva Influenza (Flu) Antiviral Drugs Product Portfolio
  144. 7.24.5 Teva Recent Developments
  145. 7.25 Takeda
  146. 7.25.1 Takeda Company Information
  147. 7.25.2 Takeda Business Overview
  148. 7.25.3 Takeda Influenza (Flu) Antiviral Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  149. 7.25.4 Takeda Influenza (Flu) Antiviral Drugs Product Portfolio
  150. 7.25.5 Takeda Recent Developments
8 North America
  1. 8.1 North America Influenza (Flu) Antiviral Drugs Market Size by Type
  2. 8.1.1 North America Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Influenza (Flu) Antiviral Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Influenza (Flu) Antiviral Drugs Price by Type (2021-2032)
  5. 8.2 North America Influenza (Flu) Antiviral Drugs Market Size by Application
  6. 8.2.1 North America Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Influenza (Flu) Antiviral Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Influenza (Flu) Antiviral Drugs Price by Application (2021-2032)
  9. 8.3 North America Influenza (Flu) Antiviral Drugs Market Size by Country
  10. 8.3.1 North America Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Influenza (Flu) Antiviral Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Influenza (Flu) Antiviral Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Influenza (Flu) Antiviral Drugs Market Size by Type
  2. 9.1.1 Europe Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Influenza (Flu) Antiviral Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Influenza (Flu) Antiviral Drugs Price by Type (2021-2032)
  5. 9.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Application
  6. 9.2.1 Europe Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Influenza (Flu) Antiviral Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Influenza (Flu) Antiviral Drugs Price by Application (2021-2032)
  9. 9.3 Europe Influenza (Flu) Antiviral Drugs Market Size by Country
  10. 9.3.1 Europe Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Influenza (Flu) Antiviral Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Influenza (Flu) Antiviral Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Influenza (Flu) Antiviral Drugs Market Size by Type
  2. 10.1.1 China Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Influenza (Flu) Antiviral Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Influenza (Flu) Antiviral Drugs Price by Type (2021-2032)
  5. 10.2 China Influenza (Flu) Antiviral Drugs Market Size by Application
  6. 10.2.1 China Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Influenza (Flu) Antiviral Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Influenza (Flu) Antiviral Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Influenza (Flu) Antiviral Drugs Market Size by Type
  2. 11.1.1 Asia Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Influenza (Flu) Antiviral Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Influenza (Flu) Antiviral Drugs Price by Type (2021-2032)
  5. 11.2 Asia Influenza (Flu) Antiviral Drugs Market Size by Application
  6. 11.2.1 Asia Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Influenza (Flu) Antiviral Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Influenza (Flu) Antiviral Drugs Price by Application (2021-2032)
  9. 11.3 Asia Influenza (Flu) Antiviral Drugs Market Size by Country
  10. 11.3.1 Asia Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Influenza (Flu) Antiviral Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Influenza (Flu) Antiviral Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Influenza (Flu) Antiviral Drugs Market Size by Type
  2. 12.1.1 SAMEA Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Influenza (Flu) Antiviral Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Influenza (Flu) Antiviral Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Influenza (Flu) Antiviral Drugs Market Size by Application
  6. 12.2.1 SAMEA Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Influenza (Flu) Antiviral Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Influenza (Flu) Antiviral Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Influenza (Flu) Antiviral Drugs Market Size by Country
  10. 12.3.1 SAMEA Influenza (Flu) Antiviral Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Influenza (Flu) Antiviral Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Influenza (Flu) Antiviral Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Influenza (Flu) Antiviral Drugs Value Chain Analysis
  2. 13.1.1 Influenza (Flu) Antiviral Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Influenza (Flu) Antiviral Drugs Production Mode & Process
  6. 13.2 Influenza (Flu) Antiviral Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Influenza (Flu) Antiviral Drugs Distributors
  9. 13.2.3 Influenza (Flu) Antiviral Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst